2015 Fiscal Year Final Research Report
The development of novel therapeutic system using anaerobic bacteria as the drug delivery carrier.
| Project/Area Number |
24590203
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Teikyo Heisei University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIDA Isao 帝京平成大学, 薬学部, 教授 (00415556)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Keywords | 抗腫瘍薬 / DDS / 嫌気性菌 / ビフィズス菌 / イムノトキシン / 抗体薬物複合体 |
|---|
| Outline of Final Research Achievements |
In this study, we analyzed the anti-tumor effect of the recombinant bifidobacteria secreting the immunotoxin, anti-EGFR antibody / Pseudomonas Exotoxin A fusion protein, in animal models of human cancer. As the result, the bacteria exhibits significant anti-tumor activity on human cancer cells expressing EGFR. In addtion, we demonstrated that this immunotoxin specifically inhibited the proliferation of target cancer cells both in molecular and cellular level. Taken together, we consider that this bifidobacteria can be actually utilized for the novel therapy for cancers.
|
| Free Research Field |
医療系薬学
|
